Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Akoya Biosciences (AKYA)
NASDAQ:AKYA
Holding AKYA?
Track your performance easily
Earnings Data
Report Date
Mar 10, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.16Last Year’s EPS
-$0.22Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 14, 2024
|% Change Since: -20.45%
|Next Earnings Date:Mar 10, 2025
Earnings Call Sentiment|Neutral
The earnings call reflects a challenging quarter for Akoya Biosciences, with significant revenue declines and underperformance in instrument sales due to market constraints. However, improvements in operational efficiencies and strategic advancements in the clinical pipeline provide a positive outlook for long-term growth.Company Guidance
During the AKYA Q3 2024 earnings call, executives provided guidance indicating a challenging year, with full-year revenue now expected to range between $80 million and $85 million, a revision from the previous estimate of $96 million to $104 million. The company reported a Q3 revenue of $18.8 million, a 25% decrease year-over-year, with instrument sales particularly impacted, totaling $5.7 million, a 53% decline from the previous year. Despite these challenges, Akoya highlighted operational efficiencies, achieving a gross margin of 62.3%, up from 60.6% last year, and a notable reduction in operating expenses by 25%, lowering the loss from operations by 28% to $8.3 million. The company remains optimistic about the long-term growth prospects, driven by advancements in their reagent and companion diagnostic pipeline, and emphasized a commitment to strategic alternatives to sustain growth and profitability.Improved Gross Margin
Gross margin improved to 62.3% from 60.6% in the prior year period, driven by operational efficiencies and the manufacturing center of excellence.
Operational Restructuring Success
Operating expenses decreased by 25% year-over-year to $20.1 million, improving the loss from operations by 28%.
Reagent Revenue Growth
Reagent revenue increased by 11% year-over-year, totaling $6.3 million, indicating strong demand and utilization.
Expansion in Clinical Pipeline
Significant progress in clinical business with promising partnerships, including Acrivon Therapeutics and NeraCare, positioning for future growth.
---
AKYA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
AKYA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $3.13 | $2.41 | -23.00% |
| Aug 05, 2024 | $2.15 | $2.01 | -6.51% |
| May 13, 2024 | $4.12 | $2.90 | -29.61% |
| Mar 04, 2024 | $5.98 | $5.10 | -14.72% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Akoya Biosciences (AKYA) report earnings?
Akoya Biosciences (AKYA) is schdueled to report earning on Mar 10, 2025, TBA Not Confirmed.
What is Akoya Biosciences (AKYA) earnings time?
Akoya Biosciences (AKYA) earnings time is at Mar 10, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AKYA EPS forecast?
AKYA EPS forecast for the fiscal quarter 2024 (Q4) is -$0.16.
---